touchONCOLOGY spoke to Dr Lizza Hendriks (Maastricht University, The Netherlands) to discuss her presentation at the European Lung Cancer Summit 2022, providing an update on the use of immunotherapy for the treatment for non-oncogene addicted non-small cell lung cancer with brain metastases.
- Could you give us a brief overview of current treatments for non-oncogene addicted non-small cell lung cancer (NSCLC) with brain metastases? 00:17-00:48
- What clinical evidence supports the use of immunotherapy in this setting? 00:48-01:44
- What factors should influence the decision to use immunotherapy? 01:44-02:21
- What unanswered questions remain? 02:21-03:08
Speaker Disclosure: Lizza Hendriks discloses grant/research support from AstraZeneca, Roche, Boehringer and Takeda. She is a member of the Advisory Board for: BMS, Eli Lilly, Roche Genentech, Pfizer, Takeda, MSD, Boehringer Ingelheim, Novartis, Amgen and Janssen. She is a speaker’s bureau participant with: MSD and Lilly. Other financial or material support includes: travel/conference reimbursement from Roche Genentech (self); mentorship program with key opinion leaders funded by AstraZeneca; fees for educational webinars from: Benecke, Medtalks, VJOncology (self) and high5oncology (institution); interview sessions funded by Roche Genentech, Bayer and Lilly (institution); local principle investigator of clinical trials: AstraZeneca, Novartis, BMS, MSD /Merck, GSK, Takeda, Blueprint Medicines, Roche Genentech, Janssen Pharmaceuticals and Mirati.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the European Lung Cancer Summit 2022
Share this Video
Related Videos In Lung Cancer
Gerard Zalcman, ESMO 2022: IFCT-1701 phase III trial, investigating nivolumab plus ipilimumab in advanced non-small cell lung cancer
First-line immunotherapy is a standard treatment for patients with advanced non-small cell lung cancer. Prof. Gerard Zalcman (Bichat Hospital, Assistance Publique-Hôpitaux de Paris; Institute of Cancer AP-HP Nord, Paris, France) joins touchONCOLOGY to discuss the IFCT-1701 phase III trial, investigating nivolumab plus ipilimumab, aiming to assess if 6-months nivolumab/ipilimumab duration was equivalent to continuation until progression […]
Charles Swanton, ESMO 2022: Mechanism of action and an actionable inflammatory axis for air pollution may induce NSCLC in never-smokers
The mechanistic basis for non-small cell lung cancer (NSCLC) initiation in never smokers is unknown. The air pollutant, particulate matter, is known to be associated with the risk of NSCLC, however a direct cause and mechanism remains difficult to achieve. Prof. Charles Swanton (Francis Crick Institute, London, UK) joins touchONCOLOGY to discuss his study into […]
Catherine A. Shu, ASCO 2022: Updated results from the CHRYSALIS-2 of amivantamab and lazertinib in patients with advanced NSCLC
Dr Catherine Shu (Columbia University Irving Medical Center, New York, NY, USA) discusses the findings of the CHRYSALIS-2 study, which supports the use of amivantamab in certain groups of patients with advanced non-small-cell lung cancer (NSCLC) and represents a chemotherapy-free regimen. The abstract ‘Amivantamab and lazertinib in patients with EGFR-mutant non–small cell lung (NSCLC) after […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!